var title_f21_8_21632="Duodenal carcinoid Endosc";
var content_f21_8_21632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carcinoid tumor in the duodenum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of a duodenal carcinoid (arrow). Carcinoids can appear as small, round sessile or polypoid lesions. They usually have normal overlying mucosa and rarely ulcerate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21632=[""].join("\n");
var outline_f21_8_21632=null;
var title_f21_8_21633="Patient information: Spasmodic dysphonia (The Basics)";
var content_f21_8_21633=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83899\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/7/16496\">",
"         Larynx (voice box)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/23/26994\">",
"         Patient information: Dysarthria (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/2/34849\">",
"         Patient information: Dystonia (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Spasmodic dysphonia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/spasmodic-dysphonia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2368302378\">",
"      <span class=\"h1\">",
"       What is spasmodic dysphonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Spasmodic dysphonia is a rare disorder that affects the muscles that control the vocal cords in your throat (",
"      <a class=\"graphic graphic_figure graphicRef83209 \" href=\"UTD.htm?16/7/16496\">",
"       figure 1",
"      </a>",
"      ). The disorder makes it hard for you to speak normally.",
"     </p>",
"     <p>",
"      Spasmodic dysphonia affects mostly women and usually starts in middle age (when the person is between 30 and 50 years old).",
"     </p>",
"     <p>",
"      There are 2 main types spasmodic dysphonia:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The most common type, called the &ldquo;",
"        <strong>",
"         ad",
"        </strong>",
"        ductor type,&rdquo; causes a person&rsquo;s speech to sound halting, strained, and strangled.",
"       </li>",
"       <li>",
"        The other type, called the &ldquo;",
"        <strong>",
"         ab",
"        </strong>",
"        ductor type,&rdquo; a causes a person&rsquo;s speech to sound breathy, like a whisper.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302410\">",
"      <span class=\"h1\">",
"       What causes spasmodic dysphonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors don&rsquo;t know what causes it. They do know it happens because the muscles in the throat freeze up or spasm. They also suspect the condition happens because of a problem in a part of the brain that controls movement.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302425\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if you develop a new speech problem that does not go away, see a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302440\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Sometimes doctors use a special tool called a &ldquo;nasopharyngoscope&rdquo; to look at the vocal cords.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302455\">",
"      <span class=\"h1\">",
"       How is spasmodic dysphonia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment is injections of a medicine called botulinum toxin (also called BoTox) into the muscles in the voice box. These injections help the muscles relax and reduce the symptoms of spasmodic dysphonia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2368302470\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/2/34849?source=see_link\">",
"       Patient information: Dystonia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=see_link\">",
"       Patient information: Dysarthria (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/8/21633?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83899 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21633=[""].join("\n");
var outline_f21_8_21633=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302378\">",
"      What is spasmodic dysphonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302410\">",
"      What causes spasmodic dysphonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302425\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302440\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302455\">",
"      How is spasmodic dysphonia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2368302470\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/7/16496\">",
"      Larynx (voice box)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/23/26994?source=related_link\">",
"      Patient information: Dysarthria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/2/34849?source=related_link\">",
"      Patient information: Dystonia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_8_21634="Cervical dermatomes";
var content_f21_8_21634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Cervical dermatomes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 552px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the cervical and T1 dermatomes. There is no C1 dermatome. Patients with nerve root syndromes may have pain, paresthesias, and diminished sensation in the dermatome of the nerve that is involved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21634=[""].join("\n");
var outline_f21_8_21634=null;
var title_f21_8_21635="Finger buddy taping";
var content_f21_8_21635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Finger buddy taping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Buddy taping the injured finger to an adjacent finger provides stability while the fracture heals. Padding placed between the fingers prevents the soft tissues from becoming macerated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21635=[""].join("\n");
var outline_f21_8_21635=null;
var title_f21_8_21636="Seborrheic keratosis hyperpigmented";
var content_f21_8_21636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperpigmented seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21636=[""].join("\n");
var outline_f21_8_21636=null;
var title_f21_8_21637="Pneumothorax ex vacuo PA";
var content_f21_8_21637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of a pneumothorax ex vacuo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows right upper lobe atelectasis and a pneumothorax surrounding strictly the atelectatic lobe. After bronchoscopy and removal of the obstructing mucous plug, the pneumothorax disappeared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21637=[""].join("\n");
var outline_f21_8_21637=null;
var title_f21_8_21638="CJD pathology low power";
var content_f21_8_21638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80949&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Low power photomicrograph of classic CJD showing fine vacuolation distributed throughout the cortical gray matter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry G Brown, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21638=[""].join("\n");
var outline_f21_8_21638=null;
var title_f21_8_21639="Papular secondary syphilis";
var content_f21_8_21639=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60313%7EID%2F65500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60313%7EID%2F65500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple slightly scaly erythematous papules are present on the trunk of this patient with papular secondary syphilis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Maculopapular rash on the palms, which rarely can be pustular, in a patient with secondary syphilis. Patients can be quite contagious at this stage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David H Martin and Tomasz F Mroczkowski. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21639=[""].join("\n");
var outline_f21_8_21639=null;
var title_f21_8_21640="Turner-Warwick incision";
var content_f21_8_21640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Turner-Warwick incision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse skin incision. Subcutaneous tissue is dissected from the anterior sheath to a point at least 2 cm below the pubis. The sheath is incised 2 cm below the pubis and at least 4 cm in length. The incision is extended cephalad along the borders of the rectus muscles. Peritoneum is incised longitudinally.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21640=[""].join("\n");
var outline_f21_8_21640=null;
var title_f21_8_21641="Bosentan: Pediatric drug information";
var content_f21_8_21641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bosentan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"    see \"Bosentan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/53/13141?source=see_link\">",
"    see \"Bosentan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tracleer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Bosentan;",
"     </li>",
"     <li>",
"      Mylan-Bosentan;",
"     </li>",
"     <li>",
"      PMS-Bosentan;",
"     </li>",
"     <li>",
"      Sandoz-Bosentan;",
"     </li>",
"     <li>",
"      Tracleer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2851892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Endothelin Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Very limited information exists; further studies are needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Full-Term Neonate: Oral: 1 mg/kg/dose twice daily short-term use (2-16 days) in three full-term neonates has been reported. In the initial report, two full-term neonates (8 days and 14 days old) with persistent pulmonary hypertension of the newborn (PPHN) and transposition of the great arteries received bosentan prior to cardiac surgery; patients also received other therapies (Goissen, 2008). A case report describes the use of bosentan monotherapy for PPHN in a full-term neonate as primary course of treatment initiated at 29 hours of life; therapy was weaned after 72 hours through the following dose reductions: 0.5 mg/kg/dose twice daily followed by 0.5 mg/kg once daily and subsequent discontinuation at 96 hours of treatment (Nakwan, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2851924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"      see \"Bosentan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"     <b>",
"      Pulmonary arterial hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;7 months and Children: Limited data exist; further studies needed (Barst, 2003; Ivy, 2004; Maiya, 2006; Rosenzweig, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Fixed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     5 to &lt;10 kg: Initial: 15.6 mg daily for 4 weeks; increase to maintenance dose of 15.6 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     10-20 kg: Initial: 31.25 mg daily for 4 weeks; increase to maintenance dose of 31.25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;20-40 kg: Initial: 31.25 mg twice daily for 4 weeks; increase to maintenance dose of 62.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight-based dosing: Children &ge;2 years: Initial: 0.75-1 mg/kg/dose twice daily for 4 weeks (maximum dose: 62.5 mg); then increase to maintenance dose of 2 mg/kg/dose twice daily (maximum dose: &le;40 kg: 62.5 mg; maximum dose: &gt;40 kg: 125 mg); a higher daily dose of  4 mg/kg/dose twice daily has been studied but has not been shown to produce higher serum concentrations than 2 mg/kg/dose and is not recommended by authors of the trial (Beghetti, 2009; Beghetti, 2009a, Villanueva, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &lt;40 kg: Initial and maintenance: 62.5 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;40 kg: Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily;",
"     <b>",
"      Note",
"     </b>",
"     : Doses &gt;125 mg twice daily do not provide additional benefit sufficient to offset the increased risk of hepatic injury. When discontinuing treatment, consider a reduction in dosage to 62.5 mg twice daily for 3-7 days to avoid clinical deterioration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Pulmonary arterial hypertension:",
"     </b>",
"     Initial: 62.5 mg twice daily for 4 weeks; increase to maintenance dose of 125 mg twice daily; adults &lt;40 kg should be maintained at 62.5 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;125 mg twice daily do not provide additional benefit sufficient to offset the increased risk of hepatic injury. When discontinuing treatment, consider a reduction in dosage to 62.5 mg twice daily for 3-7 days (to avoid clinical deterioration).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coadministration with protease inhibitor regimen:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment for concurrent use with atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir, lopinavir/ritonavir, ritonavir, saquinavir/ritonavir, tipranavir/ritonavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of bosentan in patients currently receiving one of these protease inhibitor regimens for at least 10 days: Begin with bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of one of these protease inhibitor regimens in patients currently receiving bosentan: Discontinue bosentan at least 36 hours prior to the initiation of an above protease inhibitor regimen. After at least 10 days of the protease inhibitor regimen, resume bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosage adjustment for concurrent use with indinavir or nelfinavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of bosentan in patients currently receiving indinavir or nelfinavir: Begin with bosentan 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coadministration of indinavir or nelfinavir in patients currently receiving bosentan: Adjust bosentan to 62.5 mg once daily or every other day based on tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh class A): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe impairment (Child-Pugh class B and C) and/or baseline transaminase &gt;3 times ULN: Use not recommended; systemic exposure significantly increased in patients with moderate impairment (not studied in patients with severe impairment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment based on serum transaminase elevation:",
"     </b>",
"     Adults: If any elevation, regardless of degree, is accompanied by clinical symptoms of hepatic injury (unusual fatigue, nausea, vomiting, abdominal pain, fever, or jaundice) or a serum bilirubin &ge;2 times ULN, treatment should be stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST/ALT &gt;3 times but &le;5 times ULN: Confirm elevation with additional test; if confirmed, reduce dose to 62.5 mg or interrupt treatment. Monitor transaminase levels at least every 2 weeks. May continue or reintroduce treatment, as appropriate, following return to pretreatment aminotransferase values. When reintroducing treatment, begin with starting dose and recheck transaminases within 3 days and at least every 2 weeks thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST/ALT &gt;5 times but &le;8 times upper limit of normal: Confirm elevation with additional test; if confirmed, stop treatment. Monitor transaminase levels at least every 2 weeks. May  reintroduce treatment, as appropriate, following return to pretreatment aminotransferase values. When reintroducing treatment, begin with starting dose and recheck transaminases within 3 days and at least every 2 weeks thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST/ALT &gt;8 times upper limit of normal: Stop treatment and do not reintroduce.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tracleer&reg;: 62.5 mg, 125 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Bosentan (Tracleer&reg;) is only available through Tracleer&reg; Access Program (T.A.P.). Only prescribers and pharmacies registered with T.A.P. may prescribe and dispense bosentan. Further information may be obtained from the manufacturer, Actelion Pharmaceuticals (1-866-228-3546 or file://www.tracleer.com/hcp/prescribing-tracleer.asp).",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089801.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089801.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2851925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be administered without regard to meals. Avoid grapefruit and grapefruit juice. Women of childbearing potential should avoid splitting, crushing, or handling broken tablets and exposure to the generated dust (tablets should be dissolved in water if necessary).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2851921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2851893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pulmonary arterial hypertension (PAH) [WHO Group I] in patients with NYHA Class II, III, or IV symptoms to improve exercise capacity and decrease the rate of clinical deterioration (FDA approved in ages &gt;12 years and adults);",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trials establishing effectiveness included primarily patients with NYHA Functional Class II-IV symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6053349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tracleer&reg; may be confused with TriCor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F142229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, flushing, hypotension, palpitation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Spermatogenesis inhibition",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, decreased hemoglobin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal hepatic function, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis, angioneurotic edema, heart failure (exacerbation), cirrhosis (prolonged therapy), hyperbilirubinemia, hypersensitivity, jaundice, leukocytoclastic vasculitis, leukopenia, liver failure (rare), neutropenia, peripheral edema, rash, thrombocytopenia, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2851896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bosentan or any component; pregnancy; concurrent use of cyclosporine or glyburide",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2854439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with low hemoglobin levels or ischemic cardiovascular disease; may cause dose-related decreases in hematocrit and hemoglobin (&ge;1 g/dL in up to 57% of patients, typically in first 6 weeks of therapy; markedly decreased hemoglobin may occur in up to 6% of patients); measure hemoglobin prior to initiating therapy, at 1 and 3 months, and every 3 months thereafter. Significant decreases in hemoglobin in the absence of other causes may warrant the discontinuation of therapy. May cause fluid retention, worsening of CHF, weight gain, and leg edema;",
"     <b>",
"      Note:",
"     </b>",
"     PAH itself may cause fluid retention and edema; if significant fluid retention occurs, further evaluation may be necessary to determine the cause and appropriate treatment or discontinuation of bosentan therapy. If pulmonary edema occurs, consider the possibility of pulmonary veno-occlusive disease (PVOD) and discontinue bosentan. Sperm count may be reduced in men during treatment; no changes in sperm function or hormone levels have been noted; fertility issues may require discussion with patient.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2851897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Women of childbearing potential should avoid splitting, crushing, or handling broken tablets and exposure to the generated dust (should be dissolved in water if necessary ).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Serious hepatic injury, including rare reports of cirrhosis and liver failure may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Dose-dependent elevations in liver aminotransferases (ALT and AST) of at least 3 times the ULN may occur at any time during therapy in up to 11% of patients; elevations in bilirubin may occur in some cases; progression of liver enzyme elevation is generally slow and asymptomatic and usually reversible after drug interruption or discontinuation of therapy. Rare cases of hepatic cirrhosis have been reported after prolonged use (&gt;12 months) and in patients receiving multiple medications. Monitor liver enzymes at baseline and monthly thereafter. Use with caution in patients with mildly impaired liver function; avoid use in moderate to severe hepatic impairment. Avoid use in patients with elevated serum transaminases (&gt;3 times ULN) at baseline; adjust dosage if elevations in liver enzymes occur during therapy. Treatment should be discontinued in patients who develop elevated transaminases (ALT or AST) in combination with symptoms of hepatic injury (unusual fatigue, jaundice, nausea, vomiting, abdominal pain, and/or fever) or elevated serum bilirubin &ge;2 times ULN. Consider the benefits of treatment versus the risk of hepatotoxicity when initiating therapy in patients with WHO Class II symptoms. Patients with WHO Class II symptoms who received bosentan demonstrated a decrease in the rate of clinical deterioration; however, only a trend for improved exercise capacity was observed. The risk of serious hepatic injury should be weighed against these benefits in this group of patients, as serious hepatic injury may preclude future use of bosentan as the disease progresses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause birth defects; use in pregnancy contraindicated",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Exclude pregnancy prior to initiation of therapy; obtain monthly pregnancy tests during treatment. Reliable contraception must be used during therapy and for 1 month after stopping treatment. Hormonal contraceptives (oral, injectable, transdermal, or implantable) may not be effective and a second method of contraception (nonhormonal) is required. Patients with tubal ligation or an implanted IUD (Copper T 380A or LNg 20) do not need additional contraceptive measures.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Because of the risks of hepatic impairment and the high likelihood of teratogenic effects, bosentan is only available through the Tracleer&reg; Access Program (T.A.P.)",
"     <b>",
"      [U.S. Boxed Warning].",
"     </b>",
"     Patients, prescribers, and pharmacies must be registered with and meet conditions of T.A.P. Call 1-866-228-3546 or visit file://www.tracleer.com/hcp/prescribing-tracleer.asp for more information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Bosentan may interact with many medications and may result in potentially serious and/or life-threatening adverse events; concurrent use with some medications is contraindicated (ie, cyclosporine, glyburide) and other medications may require dosage adjustments. Consult drug interactions database for more detailed information.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (major), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C9 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Atazanavir. Management: Concurrent use of atazanavir (without ritonavir) and bosentan is not recommended.  Bosentan dose adjustments are required when used together with atazanavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adults who have been on elvitegravir/cobicistat/emtricitabine/tenofovir for at least 10 days.  Stop bosentan for at least 36 hrs before starting the combo product; wait at least 10 days before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Bosentan may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Bosentan may decrease the serum concentration of Contraceptives (Progestins).  Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Bosentan may decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: Bosentan may decrease the serum concentration of Darunavir. Darunavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking darunavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting darunavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Bosentan may decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking fosamprenavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting fosamprenavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GlyBURIDE: May enhance the hepatotoxic effect of Bosentan. Bosentan may increase the metabolism of GlyBURIDE. GlyBURIDE may increase the metabolism of Bosentan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Bosentan may increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fluvastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Bosentan may decrease the serum concentration of Indinavir. Indinavir may increase the serum concentration of Bosentan.  Management: Initiate bosentan at, or adjust bosentan to, 62.5 mg once daily or every other day (based on tolerability) in indinavir-treated patients (see ritonavir for dosing if that agent is used). Additionally, monitor for possible reduced response to indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Bosentan may decrease the serum concentration of Lopinavir. Lopinavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking lopinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting lopinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Bosentan may decrease the serum concentration of Nelfinavir. Nelfinavir may increase the serum concentration of Bosentan.  Management: Initiate bosentan at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir.  Additionally, monitor for possible reduced clinical response to nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: Bosentan may decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. Rifampin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination). Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Bosentan may decrease the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking saquinavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting saquinavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Bosentan may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Bosentan may decrease the serum concentration of Tipranavir. Tipranavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg/day or every other day in adult patients taking tipranavir/ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting tipranavir/ritonavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Bosentan may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2851900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food does not affect bioavailability. Bosentan serum concentrations may be increased by grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F142187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: May cause birth defects; use in pregnancy is contraindicated. Exclude pregnancy prior to initiation of therapy and obtain pregnancy tests monthly during treatment. Reliable contraception must be used during therapy and for 1 month after stopping treatment. Hormonal contraceptives (oral, injectable, transdermal, or implantable) may not be effective and a second method of contraception (nonhormonal) is required. Patients with tubal ligation or an implanted IUD (Copper T 380A or LNg 20) do not need additional contraceptive measures.",
"     </b>",
"     When a hormonal or barrier contraceptive is used, one additional method of contraception is still needed if a male partner has had a vasectomy. When initiating treatment for women of reproductive potential, a negative pregnancy test should be documented within the first 5 days of a normal menstrual period and &ge;11 days after the last unprotected intercourse. A missed menses or suspected pregnancy should be reported to a healthcare provider and prompt immediate pregnancy testing. Sperm counts may be reduced in men during treatment. Women of childbearing potential should avoid splitting, crushing, or handling broken tablets and exposure to the generated dust (tablet splitting is currently outside of product labeling).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2851926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum  transaminase (AST and ALT) and bilirubin should be determined prior to the initiation of therapy and at monthly intervals thereafter. Monitor for clinical signs and symptoms of liver injury (eg, abdominal pain, fatigue, fever, jaundice, nausea, vomiting). Hemoglobin and hematocrit should be measured at baseline, after 1 and 3 months of treatment, and every 3 months thereafter.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A woman of childbearing potential must have a negative pregnancy test prior to the initiation of therapy, monthly thereafter, and 1 month after stopping therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2851922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bosentan acts as a competitive antagonist and blocks endothelin receptors on vascular endothelium and smooth muscle. Stimulation of endothelin receptors is associated with vasoconstriction and proliferation (",
"     <b>",
"      Note:",
"     </b>",
"     Patients with PAH have elevated lung tissue and plasma concentrations of endothelin). Although bosentan blocks both ET",
"     <sub>",
"      A",
"     </sub>",
"     and ET",
"     <sub>",
"      B",
"     </sub>",
"     receptors, the affinity is slightly higher for the A subtype. In clinical trials, bosentan significantly increased cardiac index and decreased pulmonary artery pressure, pulmonary vascular resistance, and mean right atrial pressure. Improvement in symptoms of PAH and exercise capacity, and a decrease in the rate of clinical deterioration were observed.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2851923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not distribute into RBCs; V",
"     <sub>",
"      d",
"     </sub>",
"     : ~18 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98% to plasma proteins (primarily albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver via cytochrome P450 isoenzymes CYP2C9 and CYP3A4 to three metabolites (one has pharmacologic activity and may account for 10% to 20% of drug effect); steady-state plasma concentrations are 50% to 65% of those attained after single dose (most likely due to autoinduction of liver enzymes); steady-state is attained within 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Healthy subjects: 5 hours; half-life may be prolonged in PAH, as AUC is 2-fold greater in adults with PAH versus healthy subjects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Biliary excretion; urine (&lt;3% as unchanged drug)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not likely to be removed (due to extensive protein binding and high molecular weight)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2851927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/53/13141?source=see_link\">",
"      see \"Bosentan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of bosentan. Some medicines should not be taken with bosentan; report the use of other medications, nonprescription medications, and herbal or natural products to physician and pharmacist; avoid the herbal medicine St John's wort. Bosentan may cause liver damage and low red blood cell levels; blood tests to check for these side effects must be performed frequently. Notify physician if persistent headache or GI problems, swelling of extremities, or unusual weight gain, chest pain or palpitations, unusual fatigue or weakness, yellowing of skin or eyes, change in color of stool or urine, or other persistent reactions occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Bosentan may cause major birth defects and must not be taken by women who are pregnant or who may become pregnant. Women who are able to become pregnant must use two effective birth control methods while taking bosentan and for 1 month after stopping treatment [except for patients with tubal ligation or an implanted IUD (copper T 380A or LNg20); no other contraceptive measures are required for these patients]. Bosentan may decrease the effectiveness of hormonal contraceptives, including birth control pills, skin patches, shots, and implants; hormonal contraceptives should not be the only contraceptive method in patients receiving bosentan. Pregnancy tests (either urine or blood tests) must be performed before starting bosentan therapy, every month while taking the medication, and 1 month after stopping therapy in women who are able to become pregnant. Notify physician immediately if you think you might be pregnant. Do not crush tablets; women who are able to become pregnant should avoid exposure to bosentan powder (dust) from cutting tablets; tablets should be dissolved in water if necessary. Reduced sperm counts may occur in men taking bosentan; talk to the healthcare provider if fertility issues are important.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F2854701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The addition of bosentan to epoprostenol therapy in 8 children (8-18 years of age) with idiopathic PAH allowed for a reduction in the epoprostenol dose (and its associated side effects) in 7 of the 8 children. Epoprostenol was able to be discontinued in 3 of the 8 children (Ivy, 2004). The results from the European postmarketing surveillance program in children 2-11 years of age confirm the need for monthly measurement of liver aminotransferases in pediatric patients for the duration of bosentan treatment (Beghetti, 2008).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Clinical studies in adults have shown that bosentan was",
"     <b>",
"      not",
"     </b>",
"     effective in the treatment of CHF in patients with left ventricular dysfunction; hospitalizations for CHF were more common during the first 1-2 months after initiation of the drug.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F2932641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Tablets are not scored; a commercial pill cutter should be used to prepare a 31.25 mg dose from the 62.5 mg tablet; the half-cut 62.5 mg tablets are stable for up to 4 weeks when stored at room temperature in the high-density polyethylene plastic bottle provided by the manufacturer. Since bosentan is classified as a teratogen (Pregnancy Risk Factor X), individuals should avoid exposure to bosentan powder (dust) by taking appropriate measures (eg, using gloves and mask); women of childbearing potential should avoid exposure to dust generated from broken or split tablets.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Crushing of the tablets is not recommended; bosentan tablets will disintegrate rapidly (within 5 minutes) in 5-25 mL of water to create a suspension. An appropriate aliquot of the suspension can be used to deliver the prescribed dose. Any remaining suspension should be discarded. Bosentan should not be mixed or dissolved in liquids with a low (acidic) pH (eg, fruit juices) due to poor solubility; the drug is most soluble in solutions with a pH &gt;8.5.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adatia I, \"Improving the Outcome of Childhood Pulmonary Arterial Hypertension: The Effect of Bosentan in the Setting of a Dedicated Pulmonary Hypertension Clinic,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 46(4):705-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16098439/pubmed\" id=\"16098439\" target=\"_blank\">",
"        16098439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Apostolopoulou SC, Manginas A, Cokkinos DV, et al, \"Long-Term Oral Bosentan Treatment in Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease: A 2-Year Study,\"",
"      <i>",
"       Heart",
"      </i>",
"      , 2007, 93(3):350-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16980516/pubmed\" id=\"16980516\" target=\"_blank\">",
"        16980516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barst RJ, Ivy D, Dingemanse J, et al, \"Pharmacokinetics, Safety, and Efficacy of Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension,\"",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2003, 73(4):372-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/12709727/pubmed\" id=\"12709727\" target=\"_blank\">",
"        12709727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beghetti M, \"Bosentan in Pediatric Patients With Pulmonary Arterial Hypertension,\"",
"      <i>",
"       Curr Vasc Pharmacol",
"      </i>",
"      , 2009, 7(2):225-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/19356006/pubmed\" id=\"19356006\" target=\"_blank\">",
"        19356006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beghetti M, \"Current Treatment Options in Children With Pulmonary Arterial Hypertension and Experiences With Oral Bosentan,\"",
"      <i>",
"       Eur J Clin Invest",
"      </i>",
"      , 2006, 36(Suppl 3):16-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16919006/pubmed\" id=\"16919006\" target=\"_blank\">",
"        16919006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beghetti M, Haworth SG, Bonnet D, et al, \"Pharmacokinetic and Clinical Profile of a Novel Formulation of Bosentan in Children With Pulmonary Arterial Hypertension: The FUTURE-1 Study,\"",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2009a, 68(6):948-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/20002090/pubmed\" id=\"20002090\" target=\"_blank\">",
"        20002090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beghetti M, Hoeper MM, Kiely DG, et al, \"Safety Experience With Bosentan in 146 Children 2-11 Years Old With Pulmonary Arterial Hypertension: Results From the European Postmarketing Surveillance Program,\"",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 2008, 64(2):200-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/18414142/pubmed\" id=\"18414142\" target=\"_blank\">",
"        18414142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carter NJ and Keating GM, \"Bosentan: In Pediatric Patients With Pulmonary Arterial Hypertension,\"",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2010, 12(1):63-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/20034342/pubmed\" id=\"20034342\" target=\"_blank\">",
"        20034342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilbert N, Luther YC, Miera O, et al, \"Initial Experience With Bosentan (Tracleer&reg;) as Treatment for Pulmonary Arterial Hypertension (PAH) Due to Congenital Heart Disease in Infants and Young Children,\"",
"      <i>",
"       Z Kardiol",
"      </i>",
"      , 2005, 94(9):570-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16142516 /pubmed\" id=\"16142516 \" target=\"_blank\">",
"        16142516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goissen C, Ghyselen L, Tourneux P, et al, \"Persistent Pulmonary Hypertension of the Newborn With Transposition of the Great Arteries: Successful Treatment With Bosentan,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 2008, 167(4):437-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/17701214/pubmed\" id=\"17701214\" target=\"_blank\">",
"        17701214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ivy DD, Doran A, Claussen L, et al, \"Weaning and Discontinuation of Epoprostenol in Children With Idiopathic Pulmonary Arterial Hypertension Receiving Concomitant Bosentan,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2004, 93(7):943-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/15050507/pubmed\" id=\"15050507\" target=\"_blank\">",
"        15050507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ivy DD, Rosenzweig EB, Lemari&eacute; JC, et al, \"Long-Term Outcomes in Chidren With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2010, 106(9):1332-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/21029834/pubmed\" id=\"21029834\" target=\"_blank\">",
"        21029834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lunze K, Gilbert N, Mebus S, et al, \"First Experience With an Oral Combination Therapy Using Bosentan and Sildenafil for Pulmonary Arterial Hypertension,\"",
"      <i>",
"       Eur J Clin Invest",
"      </i>",
"      , 2006, 36 Suppl 3:32-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16919008/pubmed\" id=\"16919008\" target=\"_blank\">",
"        16919008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maiya S, Hislop AA, Flynn Y, et al, \"Response to Bosentan in Children With Pulmonary Hypertension,\"",
"      <i>",
"       Heart",
"      </i>",
"      , 2006, 92(5):664-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16216850/pubmed\" id=\"16216850\" target=\"_blank\">",
"        16216850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nakwan N, Choksuchat D, Saksawad R, et al, \"Successful Treatment of Persistent Pulmonary Hypertension of the Newborn With Bosentan,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2009, 98(10):1683-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/19523174/pubmed\" id=\"19523174\" target=\"_blank\">",
"        19523174",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenzweig EB, Ivy DD, Widlitz A, et al, \"Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension,\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 46(4):697-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16098438/pubmed\" id=\"16098438\" target=\"_blank\">",
"        16098438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitbon O, Beghetti M, Petit J, et al, \"Bosentan for the Treatment of Pulmonary Arterial Hypertension Associated With Congenital Heart Defects,\"",
"      <i>",
"       Eur J Clin Invest",
"      </i>",
"      , 2006, 36(Suppl 3):25-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/8/21641/abstract-text/16919007/pubmed\" id=\"16919007\" target=\"_blank\">",
"        16919007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Villanueva D. Medical Information Manager, Actelion, personal correspondence, March 2006.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13087 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21641=[""].join("\n");
var outline_f21_8_21641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708663\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142201\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142202\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851892\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442087\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851924\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142181\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142166\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217337\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874386\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851925\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851921\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851893\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6053349\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142229\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851896\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2854439\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851897\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142217\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142174\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851900\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142176\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142187\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851926\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851922\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851923\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2851927\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2854701\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2932641\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=related_link\">",
"      Bosentan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/53/13141?source=related_link\">",
"      Bosentan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_8_21642="Treatment of small bowel neoplasms";
var content_f21_8_21642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of small bowel neoplasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/8/21642/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/8/21642/contributors\">",
"     James C Cusack, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/8/21642/contributors\">",
"     Michael J Overman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/8/21642/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/8/21642/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/8/21642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/8/21642/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/8/21642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tumors, both malignant and benign, arise within the small intestine. Malignant tumors include adenocarcinomas, carcinoids, sarcomas, and lymphomas, while benign lesions include adenomas, leiomyomas, lipomas, and hamartomas.",
"   </p>",
"   <p>",
"    The treatment of the various types of neoplasms that arise in the small bowel will be reviewed here. The epidemiology, clinical manifestations, diagnosis, and staging of small bowel tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10937?source=see_link\">",
"     \"Diagnosis and staging of small bowel neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADENOCARCINOMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Locoregional disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized adenocarcinomas of the small bowel are best managed with wide segmental surgical resection. Resection of the primary and investing mesentery achieves surgical clearance of both the primary and the regional nodes at risk for metastases, and provides important staging information that impacts decisions regarding the need for adjuvant therapy (see below). However, resection of adequate mesentery may be limited by the proximity of the nodes or tumor to the superior mesenteric artery.",
"   </p>",
"   <p>",
"    Pancreaticoduodenectomy is required for tumors involving the first and second portions of the duodenum. Some surgeons promote pancreaticoduodenectomy rather than wide local excision as a superior operation for all duodenal adenocarcinomas because of its more radical clearance of the tumor bed and regional lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, this is not necessary for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unlike pancreatic cancers, which diffusely infiltrate into the surrounding soft tissues, the extension of duodenal adenocarcinomas into adjacent tissues is usually a more localized process, and tumor-free resection margins may be obtained without resection of adjacent organs and soft tissues. Because a negative margin is critical to a curative procedure, the margin status of the resected specimen must be confirmed on frozen-section and subsequent permanent histologic sections [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/1,3,4\">",
"       1,3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of retrospective studies have not shown a survival benefit for pancreaticoduodenectomy as compared to segmental resection [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/5-9\">",
"       5-9",
"      </a>",
"      ]. The largest series, from the Mayo Clinic, analyzed 68 patients with duodenal adenocarcinoma; 50 underwent radical surgery (pancreaticoduodenectomy or total pancreatectomy) while 18 had limited surgery (segmental duodenal resection or transduodenal excision) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/10\">",
"       10",
"      </a>",
"      ]. There was no significant difference between the two groups in terms of five-year overall survival (52 percent versus 61 percent), rate of margin-negative resections, or local recurrence rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations support the view that segmental resection provides an equivalent survival benefit to that of a more extensive resection for lesions in the distal third or fourth portions of the duodenum, and satisfies the principle of en bloc resection without the morbidity of a pancreaticoduodenectomy. As long as a margin-negative resection can be obtained, segmental resection is preferred over pancreaticoduodenectomy for tumors arising in the third and fourth portions of the duodenum to the left of the superior mesenteric artery.",
"   </p>",
"   <p>",
"    Adenocarcinomas involving the jejunum or proximal ileum should be treated by wide excision of the malignancy and surrounding tissues at risk for contiguous spread. A right colectomy is indicated for tumors of the distal ileum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of diagnosis, between 65 and 76 percent of patients with a small bowel adenocarcinoma are without distant metastases and potentially resectable; about one-half of these have regional nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In general, five-year survival rates for small bowel adenocarcinoma are worse than for similarly staged colon cancers, particularly for node-positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Nodal involvement is one of the strongest predictors of long-term survival; five-year cancer-specific survival for node-positive small bowel adenocarcinoma is between 12 and 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/13,15-19\">",
"     13,15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five-year disease-specific survival by stage (",
"    <a class=\"graphic graphic_table graphicRef59827 \" href=\"UTD.htm?7/30/7661\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/20\">",
"     20",
"    </a>",
"    ] for 4995 cases of small bowel adenocarcinoma reported to the National Cancer Data Base between 1985 and 1995 were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I - 65 percent",
"     </li>",
"     <li>",
"      Stage II - 48 percent",
"     </li>",
"     <li>",
"      Stage III - 35 percent",
"     </li>",
"     <li>",
"      Stage IV - 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in a recent SEER registry analysis of 1991 cases with stage I, II, or III disease from 1988 to 2005, five-year disease-specific survival was higher: stage I, 85 percent; stage II, 69 percent; and stage II, 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, this analysis showed that the number of lymph nodes evaluated was a strong prognostic factor with markedly improved five-year disease-specific survival in patients with &ge;8 lymph nodes evaluated: stage I, 95 percent; stage II, 83 percent; and stage III, 56 percent. These data, in conjunction with those from a second study evaluating the SEER registry, suggest that a portion of stage I or II small bowel adenocarcinomas are undergoing inadequate lymph node evaluation, and consequently being understaged (and undertreated) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. This appears to be particularly true for duodenal adenocarcinomas; in one study, the assessment of eight or more lymph nodes resulted in an improvement in disease-specific survival of 33 and 50 percent for patients with stage I and II disease, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Site also impacts on prognosis. Five-year disease-specific survival rates are worse for duodenal primaries than for tumors arising in the jejunum or ileum in most [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/12,13,19,21-24\">",
"     12,13,19,21-24",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/11,25\">",
"     11,25",
"    </a>",
"    ] series.",
"   </p>",
"   <p>",
"    Besides tumor site, and the presence of nodal and distant metastases, other poor prognostic factors include positive resection margins, lymphovascular involvement, T4 tumor stage, extent of nodal disease, and poorly differentiated histology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/3,4,11-13,16,19,23,25-30\">",
"     3,4,11-13,16,19,23,25-30",
"    </a>",
"    ]. Positive resection margins increase the rate of local failure, while lymph node involvement and transmural invasion of the bowel wall correlate with distant failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data addressing the benefit of adjuvant therapy (chemotherapy, radiation therapy [RT] or both) after resection of small bowel adenocarcinomas, and its role remains undefined. A 2007 Cochrane analysis concluded that there were no suitable trials to analyze [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rationale for use of systemic adjuvant therapy in small bowel adenocarcinoma is based upon both the known patterns of recurrence for this disease and an extrapolation from data demonstrating a significant survival benefit in patients with node-positive colon cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with completely resected small bowel adenocarcinoma, failure patterns are primarily systemic rather than local [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/10,11,29,32\">",
"     10,11,29,32",
"    </a>",
"    ]. In a representative series of 146 patients undergoing potentially curative resection of a small bowel adenocarcinoma, 56 relapsed at a median time of 25 months, and the patterns of relapse were distant (n = 33), peritoneal carcinomatosis (n = 11), abdominal wall (n = 4), and local recurrence (n = 10) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/11\">",
"     11",
"    </a>",
"    ]. One exception to this general rule is duodenal adenocarcinomas, where local failure rates as high as 41 to 50 percent are reported after surgical resection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/9,10,18,26,33\">",
"     9,10,18,26,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no prospective trials testing any adjuvant therapy strategy in small bowel adenocarcinoma, and the few retrospective studies that have addressed the issue have failed to suggest any overall survival benefit from any adjuvant approach [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/1,10,11,18,25,26,33,34\">",
"     1,10,11,18,25,26,33,34",
"    </a>",
"    ]. However, in most of these reports, the patients who were chosen for adjuvant therapy were those believed to have the highest risk of recurrence (and therefore, a worse prognosis) with surgery alone.",
"   </p>",
"   <p>",
"    The largest retrospective experience included 491 patients with small bowel adenocarcinoma at any site treated at the Mayo Clinic between 1970 and 2005, 33 of whom received 5-FU-based chemotherapy and 40 adjuvant chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/25\">",
"     25",
"    </a>",
"    ]. Neither approach was associated with better outcomes, even after adjusting for age, sex, tumor location, nodal status, and grade.",
"   </p>",
"   <p>",
"    In a smaller retrospective study of 54 patients from M D Anderson Cancer Center, in which only patients who had a complete (R0) resection and were evaluated postoperatively at the institution were included, the use of adjuvant therapy was associated with improved disease-free survival (p=0.05) but not overall survival (p=0.23) in multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Separate reports have focused on the role of adjuvant therapy after complete resection of a duodenal adenocarcinoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study from the Mayo Clinic included 68 patients who had curative resection of duodenal adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/10\">",
"       10",
"      </a>",
"      ]. Twenty-five recurred, 21 with distant disease. Seventeen patients received adjuvant chemoradiotherapy with concurrent 5-FU after complete resection, but there was no significant advantage in terms of survival or cancer recurrence.",
"     </li>",
"     <li>",
"      A similar lack of benefit for adjuvant chemoradiotherapy was noted in a multi-institutional retrospective series of 122 patients with duodenal adenocarcinoma; adjuvant chemoradiotherapy was administered to 34, and the five-year survival was no better than that of the remaining patients who did not receive it (47 versus 48 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A report from Duke University compared outcomes among 16 patients treated with surgery alone to 16 nonrandomly assigned patients treated with either postoperative or preoperative 5-FU-based chemoradiotherapy (50.4 Gy) in addition to surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/26\">",
"       26",
"      </a>",
"      ]. Adjuvant therapy did not significantly improve five-year overall survival (57 percent versus 44 percent, p = 0.42), although there was a trend favoring treatment in those who underwent a complete (R0) resection (five-year survival 83 versus 53 percent, p = 0.07), and local failure rates were lower (31 versus 44 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the lack of published data supporting a benefit from adjuvant therapy, data from a nationwide survey, a registry series from the National Cancer Data Base and a population-based French registry series reveal an increase in the use of adjuvant chemotherapy for regionally advanced small bowel adenocarcinoma over the last 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/12,13,36\">",
"     12,13,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We offer adjuvant chemotherapy to patients with lymph node-positive, completely resected small bowel adenocarcinoma, extrapolating from published data in resected node-positive colon cancer, where routine use of adjuvant chemotherapy significantly improves survival. As with node-positive colon cancer, we suggest use of an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen. Oxaliplatin plus short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (ie, FOLFOX, (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"UTD.htm?16/53/17246\">",
"     table 2",
"    </a>",
"    )) is a commonly chosen option as this was the regimen shown to improve survival over 5-FU and leucovorin alone in patients with colon cancer in the MOSAIC trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, based upon the substantial activity of the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 day) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, every 21 days) in the metastatic setting, we generally prefer this combination for adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, given the higher risk of local failure for patients with duodenal adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/9,26,33\">",
"     9,26,33",
"    </a>",
"    ] and those with a positive resection margin, we suggest 5-FU-based chemoradiotherapy in addition to a course of systemic chemotherapy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/3,10\">",
"     3,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Neoadjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although neoadjuvant chemoradiotherapy has only been studied in a very small number of patients, this approach is promising [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/26,38,39\">",
"     26,38,39",
"    </a>",
"    ]. In the largest report of 32 patients with localized duodenal adenocarcinoma, 2 of 11 patients treated with preoperative radiation therapy (RT) and concurrent 5-FU-based chemotherapy had a pathologic complete response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/26\">",
"     26",
"    </a>",
"    ]. None of the 11 had involved lymph nodes at the time of resection.",
"   </p>",
"   <p>",
"    There are no widely accepted criteria for selecting patients for a neoadjuvant approach. We consider the use of neoadjuvant chemotherapy on a case-by-case basis, mainly in patients with bulky or locally advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unresectable or metastatic disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, systemic chemotherapy for patients with advanced small bowel adenocarcinoma has been based upon treatment principles established for metastatic colorectal cancer, with a 5-FU-based regimen being used most often. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although randomized trials have not been undertaken, a number of retrospective series suggest that patients with metastatic or locally advanced unresectable small bowel adenocarcinoma who get chemotherapy live longer than do those who do not receive chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef53789 \" href=\"UTD.htm?25/37/26204\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/11,25,40-42\">",
"     11,25,40-42",
"    </a>",
"    ]. However, since it is likely that chemotherapy was offered to healthier patients with more indolent disease biology, selection bias likely accounts for at least some of these findings.",
"   </p>",
"   <p>",
"    The majority of published reports evaluating chemotherapy for small bowel adenocarcinoma are retrospective in nature. Only two prospective phase II studies have been conducted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multi-institutional Eastern Cooperative Oncology Group (ECOG) study, 39 patients with locally advanced or metastatic small bowel adenocarcinoma or ampullary adenocarcinoma received 5-FU (600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 29, and 36),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 and 29) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1 only) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/42\">",
"       42",
"      </a>",
"      ]. There were seven objective responses (two complete), for an overall response rate 18 percent, and the median survival was eight months.",
"     </li>",
"     <li>",
"      More encouraging results were noted with the CAPOX regimen (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily on days 1 through 14, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      130",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1, every 21 days) in a single institution study of 31 patients with advanced, unresectable or metastatic small bowel or ampullary adenocarcinoma conducted at M D Anderson Cancer Center [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/37\">",
"       37",
"      </a>",
"      ]. Among the 25 patients with metastatic disease, the response rate was 52 percent (with three complete responses) and median overall survival was 15.5 months. The response rate in the subgroup of 18 patients with small bowel adenocarcinoma was 61 percent versus 33 percent with ampullary adenocarcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of other regimens for the treatment of small bowel adenocarcinoma has been examined in retrospective case series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/37,40-51\">",
"     37,40-51",
"    </a>",
"    ]. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series included 80 patients with metastatic small bowel adenocarcinoma treated at M D Anderson between 1978 and 2005 with a variety of chemotherapy regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/44\">",
"       44",
"      </a>",
"      ]. Twenty-nine patients received 5-FU with a platinum (19",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , four",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , six",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      ), 41 received 5-FU based therapy without a platinum (5-FU alone in 32, FAM or 5-FU and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      in six, and other 5-FU combinations in three), and ten received non-platinum and non-5-FU based therapy",
"      <br/>",
"      <br/>",
"      Compared to other regimens, 5-FU combined with a platinum drug was associated with significantly higher objective response rates (46 percent versus 16 percent with all others) and median progression-free survival (8.7 versus 3.9 months) but median overall survival was comparable (14.8 versus 12 months).",
"     </li>",
"     <li>",
"      Another report included 93 patients with advanced small bowel adenocarcinoma (86 percent metastatic) who were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU, FOLFOX (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus leucovorin and short-term infusional 5-FU), FOLFIRI (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      plus leucovorin and short-term infusional 5-FU), or 5-FU plus leucovorin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/51\">",
"       51",
"      </a>",
"      ]. Although this was not a randomized trial, response rates were highest with FOLFOX (13 of 38 partial responses, 34 percent), and median overall survival was also highest in the patients treated with FOLFOX (17.8 months).",
"      <br/>",
"      <br/>",
"      An apparent survival advantage for",
"      <span class=\"nowrap\">",
"       fluoropyrimidine/oxaliplatin",
"      </span>",
"      combination therapy over other regimens in the setting of advanced small bowel adenocarcinoma has also been shown by others [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      are also active agents [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/40,41,45,46,49,50,53\">",
"       40,41,45,46,49,50,53",
"      </a>",
"      ]. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the series of 44 patients undergoing palliative therapy for advanced disease described above, five of the 12 patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      -based therapy (six FOLFIRI [(",
"      <a class=\"graphic graphic_table graphicRef59827 \" href=\"UTD.htm?7/30/7661\">",
"       table 1",
"      </a>",
"      )], two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      plus irinotecan, and four single agent irinotecan) had a partial response (42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/40\">",
"       40",
"      </a>",
"      ]. Less impressive results have been reported with second-line FOLFIRI after failure of initial platinum-based chemotherapy (response rate 20 percent, median progression-free survival 3.2 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The activity of first-line",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      was addressed in the series of 44 patients undergoing palliative therapy for advanced disease described above [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/40\">",
"       40",
"      </a>",
"      ]. Seven of 17 patients (41 percent) receiving a gemcitabine-based regimen (nine single agent gemcitabine, four gemcitabine plus 5-FU, four gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ) had an objective response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of biologic or targeted therapies has not been systematically studied in small bowel adenocarcinoma, and only limited data are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single case report describes benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in small bowel adenocarcinoma; however, the concurrent use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      makes it impossible to discern the individual contribution of bevacizumab to treatment benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Possible benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      was suggested in a report of four patients with advanced small bowel adenocarcinoma who received the drug in conjunction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ; two had previously failed an irinotecan-based combination regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/55\">",
"       55",
"      </a>",
"      ]. There were three objective responses, one of which was complete. Three of the four patients had wild-type K-ras tumors.",
"      <br/>",
"      <br/>",
"      An additional case report describes a minor response to single agent cetuximab in a patient with metastatic duodenal adenocarcinoma whose K-ras status was wild-type [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/56\">",
"       56",
"      </a>",
"      ]. Among patients with advanced colorectal cancer, K-ras mutations are associated with relative resistance to agents that target the epidermal growth factor receptor. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=see_link&amp;anchor=H21096055#H21096055\">",
"       \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'K-ras'",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of randomized trials comparing different chemotherapy regimens, there is no standard first-line chemotherapy approach for patients with advanced small bowel adenocarcinoma. A regimen combining a fluoropyrimidine plus a platinum-type drug is a reasonable choice. We prefer the CAPOX regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/37\">",
"     37",
"    </a>",
"    ] over other combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment of the primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative surgical resection of the primary tumor may be needed in patients with locally advanced unresectable or metastatic small bowel adenocarcinoma to prevent bowel obstruction or bleeding. For tumors located in the duodenum, radiation therapy may provide local control, and for nonsurgical palliation of duodenal obstruction, an endoscopic duodenal stent can be placed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Metastatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited information is available regarding metastasectomy for small bowel adenocarcinoma. Two series report no long-term survivors among a small number of patients undergoing surgery for hepatic metastases from small bowel adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, potential benefit for hepatic resection is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adam and colleagues reported encouraging data in a large series of patients with hepatic metastases from a noncolorectal cancer primary that included 28 patients with jejunal or ileal adenocarcinoma and 12 patients with a duodenal adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/59\">",
"       59",
"      </a>",
"      ]. Five-year survival postresection was 49 percent for the",
"      <span class=\"nowrap\">",
"       jejunal/ileal",
"      </span>",
"      group and 21 percent for the duodenal group.",
"     </li>",
"     <li>",
"      In a case-control study from Johns Hopkins evaluating the benefit of resection of synchronous hepatic metastases for periampullary tumors, two patients had duodenal adenocarcinoma, one of whom represented the longest survivor at 39.5 months [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cytoreductive surgery and intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term survival has been reported after aggressive cytoreduction surgery and intraperitoneal hyperthermic chemotherapy in a handful of highly selected patients with peritoneal carcinomatosis from a small bowel adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Experience with this approach, which is more commonly applied to patients with pseudomyxoma peritonei or malignant peritoneal mesothelioma, is very limited. Patients being considered for this approach should be referred to a center with expertise in the management of peritoneal surface malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CARCINOID TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoids are generally indolent tumors. Five-year survival rates for small bowel carcinoids are between 52 and 100 percent depending upon the stage of disease (",
"    <a class=\"graphic graphic_table graphicRef58532 \" href=\"UTD.htm?41/15/42236\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/12,28,63,64\">",
"     12,28,63,64",
"    </a>",
"    ]. The observed survival rates for almost 3000 cases of gastrointestinal (GI) neuroendocrine tumors diagnosed between 1990 and 2000 in the NCI SEER (Surveillance, Epidemiology and End Results) database stratified by stage of disease are outlined in the table (",
"    <a class=\"graphic graphic_figure graphicRef74943 \" href=\"UTD.htm?40/30/41455\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/65\">",
"     65",
"    </a>",
"    ]. More specifically, five- and ten-year overall survival rates, stratified according to stage, for 214 cases of jejunoileal carcinoids seen at a single German institution over a 24-year period were [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      &ndash; 100 percent at both 5 and 10 years",
"     </li>",
"     <li>",
"      Stage III &ndash; 97 percent at five years; 85 percent at 10 years",
"     </li>",
"     <li>",
"      Stage IV&ndash; 85 percent at five years; 59 percent at 10 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Somewhat less favorable results were reported in a combined Swedish series of 135 patients with surgically treated small bowel carcinoids (",
"    <a class=\"graphic graphic_table graphicRef62793 \" href=\"UTD.htm?40/63/41980\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of localized disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors of the small bowel have the potential to metastasize, even when &lt;2 cm in size (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"UTD.htm?14/6/14444\">",
"     table 6",
"    </a>",
"    ). In a survey of published literature in which tumor size was reported and a distinction made between metastases to the regional nodes and distant sites, carcinoids of the small bowel less than 1.0 cm in size had nodal and distant metastases present at discovery in 12 and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/63\">",
"     63",
"    </a>",
"    ]. For tumors between 1.1 and 1.9 cm, nodal or distant metastases were present in 70 and 19 percent of patients, respectively, while carcinoids exceeding 2.0 cm were associated with nodal and distant metastases in 85 and 47 percent of cases, respectively.",
"   </p>",
"   <p>",
"    Because of this, the surgical management of small bowel carcinoids differs from that of appendiceal carcinoids (for which a local excision [appendectomy] is considered adequate for a tumor smaller than 1.5 to 2.0 cm in the absence of invasion of the mesoappendix, blood vessels, or regional nodes). Most surgeons recommend a wide en bloc resection that includes the adjacent mesentery and lymph nodes for a small bowel carcinoid of any size [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/67-73\">",
"     67-73",
"    </a>",
"    ]. This operation may cure a greater proportion of patients, and it provides better local disease control. Such a resection may be difficult at times if fibrosis and foreshortening of the mesentery are present. Outcomes are better among patients who undergo complete (R0) resection (",
"    <a class=\"graphic graphic_table graphicRef62793 \" href=\"UTD.htm?40/63/41980\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since approximately 40 percent of patients with midgut carcinoids have a second gastrointestinal (GI) tract malignancy, the entire bowel and colon should be evaluated prior to any surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Treatment of advanced disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery for metastatic carcinoid is not clearly defined. When metastatic disease is present (usually to the liver), it is necessary to establish whether the patient has symptoms of carcinoid syndrome and whether curative resection is possible. In an asymptomatic patient, if there are no contraindications to surgery, and the metastases appear resectable, then an attempt at complete extirpation is usually undertaken. Resection of hepatic metastases prolongs disease-free survival, and it may possibly increase overall survival as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various humoral factors elaborated by carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"     table 7",
"    </a>",
"    ). Two of the most common manifestations are episodic flushing and diarrhea (",
"    <a class=\"graphic graphic_table graphicRef63079 \" href=\"UTD.htm?37/54/38763\">",
"     table 8",
"    </a>",
"    ). Ninety percent of patients with carcinoid tumors and the carcinoid syndrome have metastatic disease, typically to the liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery plays a limited role in the treatment of most patients with the carcinoid syndrome because almost all have extensive unresectable metastatic disease. Symptomatic relief may be obtained by debulking surgery; however, the duration of effective relief from these palliative procedures can be short, usually less than 12 months. On the other hand, treatment with somatostatin analogs usually provides longer-term adequate symptomatic relief. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The indications for resection of the primary site in patients with metastatic disease are not well established, and there is little consensus on this issue. In general, at the time of surgical resection of metastatic disease, it is recommended to resect a primary intestinal carcinoid in order to prevent the development of fibrosing mesenteritis. However, prophylactic surgery is usually not undertaken unless surgery is being performed for another reason, or if serial CT scans demonstrate the development of fibrosing mesenteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691413#H691413\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Management of the primary site in patients with metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical procedures in patients with carcinoid syndrome are potentially hazardous due to the precipitation of carcinoid crisis during induction of anesthesia or surgical manipulation of tumors. Patients with metastatic carcinoid undergoing surgery should all receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    preoperatively to prevent carcinoid crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948942#H190948942\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Nonsurgical liver-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the hypervascular nature of carcinoid metastases, hepatic arterial embolization is frequently applied as a palliative technique in patients with hepatic metastases who are not candidates for surgical resection. The response rates associated with bland embolization or chemoembolization, as measured either by decrease in hormonal secretion or by radiographic regression, are generally greater than 50 percent. However, the duration of response can be brief, ranging from 4 to 24 months in uncontrolled series. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another form of nonsurgical liver-directed therapy is radioembolization using yttrium-labeled microspheres. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of systemic therapy for progressive metastatic carcinoid tumors is not well defined. Standard cytotoxic agents have minimal activity and are generally not recommended, regardless of the primary site. Somatostatin analogs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interferon-alfa are effective in controlling the hormonal symptoms resulting from the carcinoid syndrome, but have limited ability to reduce tumor burden. The systemic management of these tumors is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SARCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mesenchymal tumors of the gastrointestinal tract fall into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal stromal tumors (GIST), which comprise &gt;85 percent of all sarcomas arising within the gastrointestinal tract",
"     </li>",
"     <li>",
"      The various other soft tissue sarcomas that arise at other sites, including leiomyosarcoma, fibrosarcoma, liposarcoma, Kaposi's sarcoma, and angiosarcoma, collectively referred to as non-GIST gastrointestinal (GI) sarcomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GISTs and leiomyosarcomas can have a similar morphologic appearance, but their distinction is important because treatment, particularly in the setting of advanced disease, differs markedly. More than 80 percent of GISTs have activating mutations in the KIT protooncogene, which leads to constitutive expression of c-kit, a tyrosine kinase receptor. Expression of c-kit can be identified by immunohistochemical staining (IHC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10937?source=see_link&amp;anchor=H23#H23\">",
"     \"Diagnosis and staging of small bowel neoplasms\", section on 'Histology and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical treatment for localized, potentially resectable GISTs and non-GIST primary sarcomas of the small bowel is similar. In general, en bloc segmental resection with tumor-free margins is the primary treatment modality for both and preferred over peritumoral resection. Unlike adenocarcinoma and carcinoid, sarcomas infrequently metastasize to regional mesenteric lymph nodes, and routine mesenteric lymphadenectomy is neither necessary nor beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=see_link&amp;anchor=H11#H11\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Adjuvant and neoadjuvant treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before 2001, surgery was the only available treatment for GISTs. However, in approximately one-half of patients, complete resection was not possible, and median survival ranged from 10 to 23 months. Dramatic improvements in tumor control occurred with the recognition that mutational activation of KIT or a second receptor tyrosine kinase, platelet derived growth factor receptor-alpha (PDGFRA), stimulated the growth of these cancer cells, and that growth could be inhibited with orally active small molecule tyrosine kinase inhibitors (TKIs) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Among patients with overt metastatic disease, 80 percent experience an objective response or disease stability, median progression-free survival is 20 to 26 months, and median overall survival is 51 to 57 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=see_link\">",
"     \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of these agents in the setting of advanced disease prompted interest in their use as adjuvant therapy after complete resection of a GIST or as preoperative (induction or neoadjuvant) therapy in patients with locally advanced disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      was the subject of a trial conducted by the American College of Surgeons Oncology Group, in which patients with a completely resected GIST at least 3 cm in maximal diameter were randomly assigned to one year of adjuvant imatinib (400 mg daily) or placebo. Accrual to the study was halted when a planned interim analysis showed that treated patients had significantly fewer recurrences (3 versus 17 percent, hazard ratio 0.325). Although differences in overall survival have not been seen, adjuvant imatinib is considered a standard approach following complete resection of all small bowel GIST tumors &gt;3 cm.",
"     </li>",
"     <li>",
"      Given the importance of complete resection to long-term outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/74\">",
"       74",
"      </a>",
"      ], initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      might allow some patients with nonmetastatic unresectable or borderline resectable tumors to undergo complete tumor resection at a later time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These topics are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of adjuvant or neoadjuvant chemotherapy for small bowel sarcomas other than GIST tumors is undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study utilizing the National Cancer Data Base from 1985 to 1995 reported on 1441 small bowel sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/75\">",
"     75",
"    </a>",
"    ]. Tumor presentation was at a local or regional disease stage in 73 percent of cases. Significant variables for five-year disease specific survival included tumor size, histologic size, and general summary stage. Five-year disease-specific survivals according to stage were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Local - 72 percent",
"     </li>",
"     <li>",
"      Regional - 31 percent",
"     </li>",
"     <li>",
"      Distant - 7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This database predated the identification of GIST as a separate, molecularly-defined histologic subtype of small bowel sarcoma. Given the widespread use of tyrosine kinase inhibitors for patients with GISTs, current outcomes are now significantly improved for this subset of small bowel sarcomas. The prognosis of small intestine GISTs depends upon the tumor site, adequacy of resection, tumor size and mitotic activity (",
"    <a class=\"graphic graphic_table graphicRef60930 \" href=\"UTD.htm?35/23/36220\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary gastrointestinal (GI) lymphomas can be operationally defined as lymphomas in which the main bulk of disease is confined to the GI tract. The most common subtypes of primary small intestinal non-Hodgkin lymphoma are diffuse large-B cell lymphoma, enteropathy-associated T-cell intestinal lymphoma, extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), mantle cell lymphoma, and Burkitt and Burkitt-like lymphoma. Hodgkin lymphoma is extremely rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathology, clinical features, and prognosis of intestinal lymphomas may differ from lymphomas of lymph node origin. As an example, indolent lymphomas of lymph node origin are almost always disseminated at diagnosis, have frequent bone marrow involvement, generally respond to therapy, but continuously recur. Median survival can exceed 10 years, although cure is unusual. On the other hand, MALT and MALT-type lymphomas, also considered indolent forms of lymphoma, are often localized at diagnosis, and long-term disease-free survival and cure are common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, the treatment approach to a small bowel lymphoma generally parallels the standard treatment approach for that histological subtype of lymphoma arising in nodal regions. The unique situation that can arise in patients with lymphoma of the small intestine is in patients who undergo surgical resection of localized stage IE or IIE disease (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 10",
"    </a>",
"    ) for diagnostic purposes or because of the presence of obstruction or perforation. In such cases, outcomes following surgery alone are poor with five-year survival rates of approximately 45 percent for stage IE disease and 19 percent for stage IIE disease. Systemic chemotherapy is indicated in this situation, even if resection is complete.",
"   </p>",
"   <p>",
"    Although adjuvant RT has been advocated by some, the long-term adverse consequences of abdominal irradiation coupled with the efficacy of modern combination chemotherapy make this a less attractive option.",
"   </p>",
"   <p>",
"    The management and chemotherapy approach for lymphomas involving the GI tract is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     METASTATIC LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the small bowel is not uncommon in the context of widespread peritoneal carcinomatosis. However, hematogenous spread of metastatic disease to the small intestine is rare. In studies in which direct extension from an adjacent primary tumor was excluded, the most common cancers to involve the small bowel were melanoma, lung, breast, cervix, sarcoma, and colon [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/76-78\">",
"     76-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of these lesions is palliative; limited resection or intestinal bypass may be needed to relieve symptoms. For nonsurgical palliation of duodenal obstruction, an endoscopic duodenal stent can be placed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT OF BENIGN NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for benign neoplasms arising in the small bowel vary from endoscopic removal to radical resection (eg, pancreaticoduodenectomy or duodenectomy), depending upon the type of neoplasm, size, location, number, and malignant potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, simple tubular adenomas and Brunner gland tumors have a low malignant potential; they can be cured by endoscopic polypectomy, simple local resection, or submucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Villous adenomas have a malignant potential similar to their colonic counterparts; up to 30 percent may harbor malignancy, depending on size. Nevertheless, endoscopic polypectomy or simple resection is sufficient as long as no invasive carcinoma is found in the specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many clinicians advocate radical pancreaticoduodenectomy for periampullary duodenal villous adenomas because of the difficulty in making a preoperative diagnosis and in obtaining an adequate resection without sacrificing the ampulla. However, one study found that local submucosal excision produced acceptable long-term results if the tumor did not have areas of invasive cancer; 17 percent recurred after five years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/82\">",
"     82",
"    </a>",
"    ]. Periampullary adenomas containing areas of malignant growth (in situ or invasive) still require radical surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=see_link\">",
"     \"Treatment of ampullary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who have duodenal adenomas in the setting of FAP, there have been attempts to identify those at greatest risk for the development of adenocarcinoma of the duodenum. A classification system (the modified Spigelman classification, (",
"    <a class=\"graphic graphic_table graphicRef71691 \" href=\"UTD.htm?30/39/31355\">",
"     table 11",
"    </a>",
"    )) recognizes five grade scales (stages O to IV) based upon the number of polyps (1 to 4, 4 to 20, &gt;20), their size in mm (1 to 4, 5 to 10, and &gt;10), histology (tubular, tubulovillous, villous), and severity of dysplasia (mild, moderate, severe) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/83\">",
"     83",
"    </a>",
"    ]. Patients with stage IV disease appear to be at the greatest risk for developing adenocarcinoma, leading some authors to recommend prophylactic duodenectomy in this setting, although this is a controversial area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link&amp;anchor=H342946992#H342946992\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\", section on 'Spigelman classification of duodenal polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel leiomyomas occur most frequently in the jejunum, and they may reach considerable and even palpable size by the time they are diagnosed (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78186 \" href=\"UTD.htm?42/57/43921\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef60327 \" href=\"UTD.htm?43/19/44337\">",
"     picture 1",
"    </a>",
"    ). Histologically, these tumors are often difficult to distinguish from malignant leiomyosarcomas, although the distinction is important from the standpoint of resection extent.",
"   </p>",
"   <p>",
"    Determination of tumor grade may be used to assist in treatment decisions. In a series of 131 patients, for example, a mitotic index (MI) &ge;2 (defined as the number of mitoses per 50 high power fields) identified a population of patients who benefited from more extensive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/84\">",
"     84",
"    </a>",
"    ]. Despite conservative resection in 67 percent of these patients, there were no recurrences in those who had a MI &lt;2, compared to 16 percent in patients with a higher MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Lipoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel lipomas can produce many complications, including obscure GI bleeding. Lipomas of the small bowel have no malignant potential. Excision is required only if symptomatic; incidentally discovered tumors should be left untreated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Hamartomas and Peutz-Jeghers syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peutz-Jeghers syndrome is an inherited disorder characterized by mucocutaneous melanotic pigmentation and gastrointestinal polyps. The lesions are hamartomas that occur primarily in the jejunum and ileum. There are few reports of malignant transformation. Surgical treatment is limited to the segment responsible for symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/8/21642/abstract/81,85\">",
"     81,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rare overall, a variety of malignant and benign neoplasms arise within the small intestine. Malignant tumors include adenocarcinomas, carcinoids, stromal tumors (gastrointestinal stromal tumors [GISTs] and non-GIST soft tissue sarcomas), and lymphomas. The most common benign lesions arising in the small bowel are adenomas, leiomyomas, and lipomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of a small bowel tumor is often made late in the course of the disease, because these are generally rare conditions, and the symptoms are nonspecific (abdominal pain, weight loss, nausea and vomiting, occult GI tract bleeding). Early diagnosis requires a high index of suspicion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues relevant to diagnosis and staging of small bowel neoplasms are presented elsewhere. The following represent our recommendations for treatment of each tumor type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10937?source=see_link\">",
"     \"Diagnosis and staging of small bowel neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Adenocarcinoma",
"    </span>",
"   </p>",
"   <p>",
"    For localized adenocarcinomas of the first and second portion of the duodenum, we recommend pancreaticoduodenectomy rather than segmental resection (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). We suggest segmental resection rather than pancreaticoduodenectomy for lesions in the third and fourth portion of the duodenum, as long as negative resection margins can be achieved (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For localized tumors of the jejunum and proximal ileum, we recommend wide excision of the malignancy and surrounding tissues at risk for contiguous spread (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). For tumors of the distal ileum, we recommend right colectomy rather than segmental resection (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Locoregional disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest a course of postoperative chemotherapy rather than surgery alone for patients with lymph node-positive resected small bowel adenocarcinoma (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). For patients with duodenal primaries that are incompletely resected or are at a high risk for local recurrence, we suggest fluoropyrimidine-based chemoradiotherapy in addition to adjuvant systemic chemotherapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Adjuvant therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of neoadjuvant therapy is undefined. We consider this approach on a case-by case-basis in patients with bulky or locally advanced disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Neoadjuvant therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with locally advanced unresectable or metastatic disease who are able to tolerate it, we suggest systemic chemotherapy rather than supportive care alone (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). We use an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based chemotherapy regimen, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus oxaliplatin (CAPOX), as a first-line regimen. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Hepatic resection is a reasonable option for selected patients with potentially resectable liver metastases, a controlled primary site, and no extrahepatic metastases. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Metastatectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"   </p>",
"   <p>",
"    We recommend en bloc segmental resection with tumor-free margins rather than peritumoral resection as the primary treatment modality for most resectable GISTs and other primary sarcomas of the small bowel (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). We suggest initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    rather than upfront surgery for a borderline resectable or unresectable but nonmetastatic small bowel GIST tumor (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Sarcoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risks and benefits, and recommendations regarding the use of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    following complete resection of a GIST are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Carcinoid",
"    </span>",
"   </p>",
"   <p>",
"    We recommend wide en bloc segmental resection that includes the adjacent mesentery and lymph nodes for small bowel carcinoid tumors of any size rather than local excision alone (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since approximately 40 percent of patients with midgut carcinoids have a second gastrointestinal (GI) tract malignancy, the entire bowel and colon should be evaluated prior to any surgical intervention. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment of localized disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"   </p>",
"   <p>",
"    In general, the treatment approach for extranodal involvement of the intestinal tract by a lymphoma generally parallels the treatment approach for that histological subtype of lymphoma arising in nodal regions. For patients who undergo surgical resection of localized stage IE or IIE disease for diagnostic purposes or because of the presence of obstruction or perforation, we recommend the addition of chemotherapy rather than surgery alone (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link\">",
"     \"Management of gastrointestinal lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Benign lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of benign small bowel lesions must be tailored to their size, number, location, malignant potential, and whether they are symptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;For simple tubular adenomas, Brunner gland adenomas, and villous adenomas with no evidence of in situ or invasive malignancy, we recommend endoscopic polypectomy, simple local resection, or submucosal resection rather than more radical resection (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). We recommend radical resection for villous adenomas containing areas of malignant growth (in situ or invasive) (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Adenoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recommendations regarding management of duodenal adenomas in patients with familial adenomatous polyposis (FAP) are provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link&amp;anchor=H16#H16\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend open surgical resection rather than observation for most small bowel leiomyomas due to the difficulty in excluding leiomyosarcoma or a GIST tumor (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Leiomyoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Lipomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest excision only if a lipoma is symptomatic (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Lipoma'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/1\">",
"      Sohn TA, Lillemoe KD, Cameron JL, et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg 1998; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/2\">",
"      Lai EC, Doty JE, Irving C, Tompkins RK. Primary adenocarcinoma of the duodenum: analysis of survival. World J Surg 1988; 12:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/3\">",
"      Abrahams NA, Halverson A, Fazio VW, et al. Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 2002; 45:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/4\">",
"      Br&uuml;cher BL, Stein HJ, Roder JD, et al. New aspects of prognostic factors in adenocarcinomas of the small bowel. Hepatogastroenterology 2001; 48:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/5\">",
"      Joesting DR, Beart RW Jr, van Heerden JA, Weiland LH. Improving survival in adenocarcinoma of the duodenum. Am J Surg 1981; 141:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/6\">",
"      Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg 1992; 127:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/7\">",
"      van Ooijen B, Kalsbeek HL. Carcinoma of the duodenum. Surg Gynecol Obstet 1988; 166:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/8\">",
"      Kaklamanos IG, Bathe OF, Franceschi D, et al. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg 2000; 179:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/9\">",
"      Barnes G Jr, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: management and survival in 67 patients. Ann Surg Oncol 1994; 1:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/10\">",
"      Bakaeen FG, Murr MM, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 2000; 135:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/11\">",
"      Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/12\">",
"      Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/13\">",
"      Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999; 86:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/14\">",
"      Contant CM, Damhuis RA, van Geel AN, et al. Prognostic value of the TNM-classification for small bowel cancer. Hepatogastroenterology 1997; 44:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/15\">",
"      Overman MJ, Hu CY, Kopetz S, et al. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol 2012; 19:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/16\">",
"      Ouriel K, Adams JT. Adenocarcinoma of the small intestine. Am J Surg 1984; 147:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/17\">",
"      Adler SN, Lyon DT, Sullivan PD. Adenocarcinoma of the small bowel. Clinical features, similarity to regional enteritis, and analysis of 338 documented cases. Am J Gastroenterol 1982; 77:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/18\">",
"      Struck A, Howard T, Chiorean EG, et al. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. J Surg Oncol 2009; 100:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/19\">",
"      Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2010; 116:5374.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.127.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/21\">",
"      Nicholl MB, Ahuja V, Conway WC, et al. Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 2010; 17:2728.",
"     </a>",
"    </li>",
"    <li>",
"     SEER Survival Monograph: Cancer Survivor Among Adults: US Seer Program, 1988-2001, Patient and Tumor Characteristics. Cancers of the esophagus, stomach, and small intestine. NIH Pub No 07-6215, SEER Program; National Cancer Institute, Bethesda, MD 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/23\">",
"      Wu TJ, Yeh CN, Chao TC, et al. Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. World J Surg 2006; 30:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/24\">",
"      Zar N, Holmberg L, Wilander E, Rastad J. Survival in small intestinal adenocarcinoma. Eur J Cancer 1996; 32A:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/25\">",
"      Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010; 199:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/26\">",
"      Kelsey CR, Nelson JW, Willett CG, et al. Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007; 69:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/27\">",
"      Rose DM, Hochwald SN, Klimstra DS, Brennan MF. Primary duodenal adenocarcinoma: a ten-year experience with 79 patients. J Am Coll Surg 1996; 183:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/28\">",
"      Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/29\">",
"      Agrawal S, McCarron EC, Gibbs JF, et al. Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol 2007; 14:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/30\">",
"      Bauer RL, Palmer ML, Bauer AM, et al. Adenocarcinoma of the small intestine: 21-year review of diagnosis, treatment, and prognosis. Ann Surg Oncol 1994; 1:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/31\">",
"      Singhal N, Singhal D. Adjuvant chemotherapy for small intestine adenocarcinoma. Cochrane Database Syst Rev 2007; :CD005202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/32\">",
"      Moon YW, Rha SY, Shin SJ, et al. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol 2010; 136:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/33\">",
"      Poultsides GA, Huang LC, Cameron JL, et al. Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment. Ann Surg Oncol 2012; 19:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/34\">",
"      Swartz MJ, Hughes MA, Frassica DA, et al. Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg 2007; 142:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/35\">",
"      Overman MJ, Kopetz S, Lin E, et al. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol 2010; 49:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/36\">",
"      Lepage C, Bouvier AM, Manfredi S, et al. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol 2006; 101:2826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/37\">",
"      Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009; 27:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/38\">",
"      Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys 1994; 30:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/39\">",
"      Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993; 72:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/40\">",
"      Fishman PN, Pond GR, Moore MJ, et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/41\">",
"      Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/42\">",
"      Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     Enzinger PC, Zhu A, Blaszkowsky L, et al. Phae I dose fiinding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patinets with advanced gastrointestinal malignancies (abstract). Data presented at the 2005 ASCO Gastrointestinal Cancers Symposium, Miami, FL, January 27-29, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/44\">",
"      Overman MJ, Kopetz S, Wen S, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008; 113:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/45\">",
"      Locher C, Malka D, Boige V, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005; 69:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/46\">",
"      Polyzos A, Kouraklis G, Giannopoulos A, et al. Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother 2003; 15:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/47\">",
"      Crawley C, Ross P, Norman A, et al. The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 1998; 78:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/48\">",
"      Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984; 53:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/49\">",
"      Ono M, Shirao K, Takashima A, et al. Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine. Gastric Cancer 2008; 11:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/50\">",
"      Suenaga M, Mizunuma N, Chin K, et al. Chemotherapy for small-bowel Adenocarcinoma at a single institution. Surg Today 2009; 39:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/51\">",
"      Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol 2010; 21:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/52\">",
"      Tsushima T, Taguri M, Honma Y, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist 2012; 17:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/53\">",
"      Zaanan A, Gauthier M, Malka D, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011; 117:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/54\">",
"      Tsang H, Yau T, Khong PL, Epstein RJ. Bevacizumab-based therapy for advanced small bowel adenocarcinoma. Gut 2008; 57:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/55\">",
"      Santini D, Fratto ME, Spoto C, et al. Cetuximab in small bowel adenocarcinoma: a new friend? Br J Cancer 2010; 103:1305; author reply 1306.",
"     </a>",
"    </li>",
"    <li>",
"     Overman MJ, Wolff RA, Wang H. Reply: Cetuximab in small bowel adenocarcinoma: a new friend? [letter to the editor]. Br J Cancer 2010; 103:1306.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/57\">",
"      Hemming AW, Sielaff TD, Gallinger S, et al. Hepatic resection of noncolorectal nonneuroendocrine metastases. Liver Transpl 2000; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/58\">",
"      Ercolani G, Grazi GL, Ravaioli M, et al. The role of liver resections for noncolorectal, nonneuroendocrine metastases: experience with 142 observed cases. Ann Surg Oncol 2005; 12:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/59\">",
"      Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006; 244:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/60\">",
"      Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007; 110:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/61\">",
"      Jacks SP, Hundley JC, Shen P, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. J Surg Oncol 2005; 91:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/62\">",
"      Marchettini P, Sugarbaker PH. Mucinous adenocarcinoma of the small bowel with peritoneal seeding. Eur J Surg Oncol 2002; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/63\">",
"      Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/64\">",
"      Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge, SB, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010. p.181.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/66\">",
"      Landerholm K, Zar N, Andersson RE, et al. Survival and prognostic factors in patients with small bowel carcinoid tumour. Br J Surg 2011; 98:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/67\">",
"      Welch JP, Malt RA. Management of carcinoid tumors of the gastrointestinal tract. Surg Gynecol Obstet 1977; 145:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/68\">",
"      Strodel WE, Talpos G, Eckhauser F, Thompson N. Surgical therapy for small-bowel carcinoid tumors. Arch Surg 1983; 118:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/69\">",
"      Rothmund M, Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion 1994; 55 Suppl 3:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/70\">",
"      Nikou GC, Lygidakis NJ, Toubanakis C, et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005; 52:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/71\">",
"      Ito H, Perez A, Brooks DC, et al. Surgical treatment of small bowel cancer: a 20-year single institution experience. J Gastrointest Surg 2003; 7:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/72\">",
"      Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/73\">",
"      Akerstr&ouml;m G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol 1991; 30:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/74\">",
"      Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/75\">",
"      Howe JR, Karnell LH, Scott-Conner C. Small bowel sarcoma: analysis of survival from the National Cancer Data Base. Ann Surg Oncol 2001; 8:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/76\">",
"      Kadakia SC, Parker A, Canales L. Metastatic tumors to the upper gastrointestinal tract: endoscopic experience. Am J Gastroenterol 1992; 87:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/77\">",
"      Richie RE, Reynolds VH, Sawyers JL. Tumor metastases to the small bowel from extra-abdominal sites. South Med J 1973; 66:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/78\">",
"      FARMER RG, HAWK WA. METASTATIC TUMORS OF THE SMALL BOWEL. Gastroenterology 1964; 47:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/79\">",
"      Zollinger RM Jr. Primary neoplasms of the small intestine. Am J Surg 1986; 151:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/80\">",
"      Desa LA, Bridger J, Grace PA, et al. Primary jejunoileal tumors: a review of 45 cases. World J Surg 1991; 15:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/81\">",
"      Ashley SW, Wells SA Jr. Tumors of the small intestine. Semin Oncol 1988; 15:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/82\">",
"      Bjork KJ, Davis CJ, Nagorney DM, Mucha P Jr. Duodenal villous tumors. Arch Surg 1990; 125:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/83\">",
"      Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/8/21642/abstract/84\">",
"      Morgan BK, Compton C, Talbert M, et al. Benign smooth muscle tumors of the gastrointestinal tract. A 24-year experience. Ann Surg 1990; 211:63.",
"     </a>",
"    </li>",
"    <li>",
"     Sarr MG, Murr MM. Small Intestinal Neoplasms. In: Surgery: Scientific Principles and Practice, Greenfield LJ (Ed), Lippincott-Raven, 1997. p.844.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2509 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21642=[""].join("\n");
var outline_f21_8_21642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADENOCARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Locoregional disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Neoadjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unresectable or metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment of the primary tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Metastatectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cytoreductive surgery and intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CARCINOID TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of localized disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Treatment of advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Nonsurgical liver-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SARCOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Adjuvant and neoadjuvant treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      METASTATIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT OF BENIGN NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Lipoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Hamartomas and Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Benign lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Adenomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Lipomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2509|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/57/43921\" title=\"diagnostic image 1\">",
"      Malignant carcinoid ileum CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2509|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/30/41455\" title=\"figure 1\">",
"      Surv rates GI neuroendo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2509|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/19/44337\" title=\"picture 1\">",
"      Jejunal leiomyoma Gross",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/30/7661\" title=\"table 1\">",
"      TNM small bowel cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/53/17246\" title=\"table 2\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/37/26204\" title=\"table 3\">",
"      Benef chemo SB adenoCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/15/42236\" title=\"table 4\">",
"      TNM gastrointest carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/63/41980\" title=\"table 5\">",
"      Survival small bowel carcinoid tumor by stage and resection type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/6/14444\" title=\"table 6\">",
"      Incidence mets carcinoid size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/59/35771\" title=\"table 7\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38763\" title=\"table 8\">",
"      Carcinoid symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/23/36220\" title=\"table 9\">",
"      GIST progn site size mit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 10\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/39/31355\" title=\"table 11\">",
"      Modified Spigelmans score and classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33321?source=related_link\">",
"      Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10937?source=related_link\">",
"      Diagnosis and staging of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=related_link\">",
"      Epidemiology, clinical features, and types of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/7/34938?source=related_link\">",
"      Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=related_link\">",
"      Treatment of ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_8_21643="Contraindications IUD insertion";
var content_f21_8_21643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute contraindications to IUD insertion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Any type of IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible or confirmed pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe distortion of the uterine cavity (such as by fibroids or anatomic anomalies) that precludes IUD insertion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute, recent (within 3 months) or recurrent uterine infection (includes sexually transmitted, postpartum and postabortion infections)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated cervicitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active genital actinomycoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraindications to use of the Cu T 380A IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilson's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Known copper allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Contraindications to use of the LNg 20 IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Known allergy to levonorgestrel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute liver disease or liver tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Known or suspected carcinoma of the breast",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21643=[""].join("\n");
var outline_f21_8_21643=null;
var title_f21_8_21644="Tryptase and histamine collection instructions";
var content_f21_8_21644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Instructions for optimal collection and handling of blood samples for measurement of tryptase and histamine following suspected anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tryptase* (serum or plasma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        When to collect the sample:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blood should be collected between 15 minutes and 3 hours after symptom onset whenever possible; samples collected &lt;15 minutes or &gt;3 hours after symptom onset are less likely to be informative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        How to collect the sample:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blood can be drawn using usual technique. Collect blood for serum (red top tube) or plasma (tube with heparin, citrate or EDTA). A minimum of 1 mL is required.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For postmortem samples, collect blood from the femoral artery or vein, not the heart.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        How to process the sample:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum or plasma should be placed on ice and frozen as soon as possible. Samples should be shipped frozen by overnight courier if the assay cannot be performed on site.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Histamine (plasma)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        When to collect the sample:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plasma for histamine levels should be collected between 15 and 60 minutes after symptom onset; samples collected &lt;15 minutes or &gt;60 minutes after symptom onset are less likely to be informative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        How to collect the sample:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pull blood manually (DO NOT use vacuum tubes) under gentle pressure through a 20 gauge or larger needle into a syringe containing either citrate or EDTA.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        How to process the sample:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticoagulated blood should be placed on ice and centrifuged to separate plasma from cells as soon as possible, and then the plasma&nbsp;frozen until ready to be analyzed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The assay for total tryptase is standardized.",
"    <div class=\"footnotes\">",
"     * Normal values are similar in adults and in infants, children, and teens ages 6 months to 18 years. Komarow HD, Hu Z, Brittain E, et al. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009; 124:845.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Plasma is used to avoid the artifactual release of histamine from basophils that can occur during blood clotting.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21644=[""].join("\n");
var outline_f21_8_21644=null;
var title_f21_8_21645="Encephalitis clinical clues";
var content_f21_8_21645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings and possible etiologic agent(s) in encephalitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Possible infectious agent(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        General findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis",
"       </td>",
"       <td>",
"        Herpes simplex virus (infant only), enterovirus (in infants),",
"        <em>",
"         Coxiella burnetii",
"        </em>",
"        ; any severe hepatitis can cause encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lymphadenopathy",
"       </td>",
"       <td>",
"        HIV, Epstein-Barr virus, cytomegalovirus, measles virus, rubella virus, West Nile virus,",
"        <em>",
"         Treponema pallidum",
"        </em>",
"        ,",
"        <em>",
"         Bartonella henselae",
"        </em>",
"        and other bartonella species,",
"        <em>",
"         Mycobacterium tuberculosis",
"        </em>",
"        ,",
"        <em>",
"         Toxoplasma gondii",
"        </em>",
"        ,",
"        <em>",
"         Trypansoma brucei gambiense",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parotitis",
"       </td>",
"       <td>",
"        Mumps virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rash",
"       </td>",
"       <td>",
"        Herpes simplex virus, varicella zoster virus, herpes B virus, human herpesvirus 6, West Nile virus, rubella virus, some enteroviruses, HIV,",
"        <em>",
"         Rickettsia rickettsii",
"        </em>",
"        ,",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         Borrelia burgdorferi",
"        </em>",
"        ,",
"        <em>",
"         T. pallidum",
"        </em>",
"        ,",
"        <em>",
"         Ehrlichia chaffeensis",
"        </em>",
"        ,",
"        <em>",
"         Anaplasma phagocytophilum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory tract findings",
"       </td>",
"       <td>",
"        Venezuelan equine encephalitis virus, Nipha virus, Hendra virus, influenza virus, adenovirus,",
"        <em>",
"         M. pneumoniae",
"        </em>",
"        ,",
"        <em>",
"         C. burnetii",
"        </em>",
"        ,",
"        <em>",
"         M. tuberculosis",
"        </em>",
"        ,",
"        <em>",
"         Histoplasma capsulatum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retinitis",
"       </td>",
"       <td>",
"        Cytomegalovirus,",
"        <em>",
"         T. gondii",
"        </em>",
"        , West Nile virus,",
"        <em>",
"         B. henselae",
"        </em>",
"        ,",
"        <em>",
"         T. pallidum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urinary symptoms (dysuria, urgency, incontinence)",
"       </td>",
"       <td>",
"        St. Louis encephalitis virus (during prodrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Neurologic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebellar ataxia",
"       </td>",
"       <td>",
"        Varicella zoster virus (children), Epstein-Barr virus, mumps virus, St. Louis encephalitis virus,",
"        <em>",
"         Tropheryma whipplei",
"        </em>",
"        ,",
"        <em>",
"         T. brucei gambiense",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cranial nerve abnormalities",
"       </td>",
"       <td>",
"        Herpes simplex virus, Epstein-Barr virus,",
"        <em>",
"         Listeria monocytogenes",
"        </em>",
"        ,",
"        <em>",
"         M. tuberculosis",
"        </em>",
"        ,",
"        <em>",
"         T. pallidum",
"        </em>",
"        ,",
"        <em>",
"         B. burgdorferi",
"        </em>",
"        ,",
"        <em>",
"         T. whipplei",
"        </em>",
"        ,",
"        <em>",
"         Cryptococcus neoformans",
"        </em>",
"        ,",
"        <em>",
"         Coccidioides species",
"        </em>",
"        ,",
"        <em>",
"         H. capsulatum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dementia",
"       </td>",
"       <td>",
"        HIV, human transmissible spongiform encephalopathies (sCJD and vCJD),",
"        <em>",
"         T. pallidum",
"        </em>",
"        ,",
"        <em>",
"         T. whipplei",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myorhythmia",
"       </td>",
"       <td>",
"        <em>",
"         T. whipplei",
"        </em>",
"        (oculomasticatory)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parkinsonism (bradykinesia, masked facies, cogwheel rigidity, postural instability)",
"       </td>",
"       <td>",
"        Japanese encephalitis virus, St. Louis encephalitis virus, West Nile virus, Nipah virus,",
"        <em>",
"         T. gondii",
"        </em>",
"        ,",
"        <em>",
"         T. brucei gambiense",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Poliomyelitis-like flaccid paralysis",
"       </td>",
"       <td>",
"        Japanese encephalitis virus, West Nile virus, tick-borne encephalitis virus, enteroviruses (enterovirus 71, coxsackieviruses), poliovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rhomboencephalitis",
"       </td>",
"       <td>",
"        Enterovirus 71, herpes simplex virus, West Nile virus,",
"        <em>",
"         L. monocytogenes",
"        </em>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47:303. Copyright &copy; 2008 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21645=[""].join("\n");
var outline_f21_8_21645=null;
var title_f21_8_21646="Contents: Pediatrics calculators";
var content_f21_8_21646=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatrics calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatrics calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13697\">",
"           Calculator: Apgar score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/63/5109\">",
"           Calculator: Newborn hyperbilirubinemia assessment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/15/9463\">",
"           Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9751\">",
"           Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36070\">",
"           Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35782\">",
"           Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4529\">",
"           Calculator: Body Surface Area (Mosteller, square root method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/49/43796\">",
"           Calculator: Body mass index for boys (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12596\">",
"           Calculator: Body mass index for girls (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22262\">",
"           Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/7/22646\">",
"           Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/50/35619\">",
"           Calculator: CDC weight for height percentiles for boys (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2644\">",
"           Calculator: CDC weight for height percentiles for girls (77 to 121 cm tall)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/25/16788\">",
"           Calculator: CDC/NCHS infant head circumference for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34339\">",
"           Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/10/162\">",
"           Calculator: CDC/NCHS infant weight for age percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/6997\">",
"           Calculator: CDC/NCHS infant weight for length percentiles (&lt;36 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24193\">",
"           Calculator: Glomerular filtration rate estimate by Schwartz formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/60/8129\">",
"           Calculator: Maintenance fluid calculation for children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30769\">",
"           Calculator: Mid-parental target height prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9860\">",
"           Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36485\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30213\">",
"           Calculator: WHO Assessment of Malnutrition in Boys 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/1/36885\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 0 to 2 Years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/48/30469\">",
"           Calculator: WHO Assessment of Malnutrition in Girls 2 to 5 years Old",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35315\">",
"           Calculator: WHO Infant Head Circumference for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/51/10035\">",
"           Calculator: WHO Infant Length for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12003\">",
"           Calculator: WHO Infant Weight for Age Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/54/23398\">",
"           Calculator: WHO Infant Weight for Length Percentiles (&lt; 24 months)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-ADEEAC8845-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_8_21646=[""].join("\n");
var outline_f21_8_21646=null;
var title_f21_8_21647="Biliary ascariasis";
var content_f21_8_21647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biliary ascariasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram obtained during endoscopic retrograde cholangiopancreatography shows a linear filling defect (arrow) that was later identified as an adult Ascaris lumbricoides worm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of D Ngeshwar Reddy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_8_21647=[""].join("\n");
var outline_f21_8_21647=null;
